October Upside Ranks
Qualitative relative target-touch selections · Not calibrated probabilities
Dated prices · targets are price touches, not forecasts · exact ranks are editorial judgments.
Grade legend, dates & research limits
Completed editorial grades · assessed October 6. Business = demonstrated commercial traction. Catalyst = clarity and timing of the next important test, not success odds. Target path = how demanding this list’s target is. These grades use the same rubric for all selected names; they are not native financial-model grades or statistical probabilities.
A strong / direct · B supported but conditional · C speculative or major gaps · D exceptional leap / weak bridge. A strong catalyst can fail. A fivefold target can have a D path even in a top-ranked moonshot.
Exact grading benchmarks & evidence dates
Business
How far the business inflection is demonstrated today, not source completeness.
- A — Broad, realized commercial growth or earnings; not just a plan.
- B — Real but early, concentrated or mixed operating traction.
- C — Primarily clinical/development or capacity optionality; limited realized economics.
- D — Retained facts undermine the proposed business inflection.
Catalyst
Specificity, observability and timing of a thesis-changing test inside the original window, not its chance of success.
- A — A scheduled or explicitly windowed material readout, launch or commercial ramp; repeated hard operating tests may qualify.
- B — Concrete delivery, orders or earnings tests, but diffuse timing or less discrete thesis change.
- C — A real milestone with important acceptance/economics/timing gaps.
- D — No supported material in-window test.
Target path
Burden of reaching THIS tier target from the dated baseline; not an absolute odds estimate.
- A — Comparatively direct earnings/recognition bridge in retained evidence; still conditional.
- B — Recognizable bridge, but meaningful premium, execution or share-claim sensitivity.
- C — Speculative extension or binary rerating beyond established economics; small-base elasticity is not a forecast.
- D — Exceptional leap far beyond retained cases, with major scale/valuation/financing obstacles.
No bell curve, numeric weights, A+ grades, probability conversion or grade-based reranking. Same rubric for incumbents and additions; target-path grades vary by tier. A catalyst can fail. No synchronized chart grading because technical coverage is not comparable across all 19.
Assessment October 6 of retained evidence, not an October 6 source refresh. Baseline October 1; existing remaining touch window October 4, 2026 to exclusive October 1, 2027. Original source cutoff October 3; additions retrieved October 4; Bloom narrative retrieved October 5 UTC. Original publication dates remain attached to sources.
Original conservative research grades remain in each full story. Partial financial underwriting remains partial: completed qualitative grades do not certify current cash, target dilution, clinical efficacy or funded forecasts. No chart grade is invented from unmatched technical snapshots.
Targets use October 1, 2026 baseline quotes, which are not live prices. The price-touch window is October 4, 2026 to exclusive October 1, 2027, not the price at expiry. Exact ordinal differences are low-confidence editorial judgments; absolute likelihood may be low.
Original financial source cutoff: October 3, 2026, 07:14:12.687379 UTC. Biotech sources retrieved October 4 with original publication dates retained. Bloom’s power and policy narrative reviewed October 4 ET (sources retrieved October 5 UTC). Publication does not clear research or model limitations. No calibrated odds.
TWST · Twist Bioscience
+35% Upside · #10Oct1 baseline: USD 188.05. Historical daily quote retrieved Oct4.
The investment story
Thesis
Growing demand for synthetic DNA and protein-design tools could lift sales and cash flow without requiring a successful drug trial.
What could move the stock
Growing demand for synthetic DNA and protein-design tools could lift sales and cash flow without requiring a successful drug trial.
Next catalyst
Next annual outlook and conversion of protein-design usage into billed sales.
Major risk
The share price already expects growth; better sales must translate into cash.
Editorial grades · October 6 assessment
Same rubric for every selected company. Business is demonstrated traction; Catalyst is the timing and clarity of a test, not its chance of success. Target path changes with the target burden.
+35% Upside
Business · B
DNA/protein growth and rising gene shipments support repeat experimental demand; the AI-specific sales share is not verified.
Catalyst · B
The next annual outlook and billed protein-design usage provide tests; the November reporting window is cadence inference.
Target path · B
Repeat DNA demand and improved cash conversion could justify a modest rerating; a funded target-specific valuation is not established.
Strongest countercase
Recurring losses, valuation and cash conversion matter more than an isolated disposal gain.
Confidence & coverage
Low for target touch and adjacent ordering; moderate for the descriptive assessment of retained facts. Partial financial underwriting; current cash and target-dependent dilution unresolved.
Grade evidence & preserved research grades
Editorial reader v2 is separate from native financial certification. The original conservative evidence/path grades below have not been upgraded or overwritten.
+35% Upside original research grades
Evidence: not supplied; operating pathway: not supplied; feasibility: not supplied.
- TWST-news
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-submissions
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-Q3-alt
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-Q3-pdf
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-10Q
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-Aug19
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-Aug18
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-TuneLab
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-Aug5
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied
Detailed research, financial evidence & sources
Business
Synthetic DNA/protein and NGS workflow supplier; not a clinical therapeutic binary
Financial quality
Q3 DNA/protein $56.571m versus $40.773m; NGS $61.805m versus $55.284m. Actual repeat experimental demand and 369k genes shipped versus 237k, not hardware placements. No verified AI-specific sales share or quantified committed TuneLab backlog. Prior Q3 profit contains $48.847m business-sale gain; use recurring operating loss instead.
Claims and dilution
Cover shares precede August offering. Add priced 3.59375m only in conditional closing branch. $5m variable-share Invenra transfer obligation is not fixed share count and optional extension $10m stock is contingent. $200m unused June ATM is not opening cash. Options require strike schedule, not all shares at weighted strike. PSUs and new awards unresolved.
Guide / interpretation
{"FY2026RevenueUSDm":null,"reason":"Detailed issuer earnings PDF timed out; accessible attributed release only refers to report. Do not turn search snippet into verified guidance."}
Concrete catalysts — not efficacy promises
- Next FY2026 results/initial FY2027 outlook around November 2026: inferred annual reporting cadence, no confirmed future issuer date retained
- Through following quarters: conversion of TuneLab/protein-design usage into billed sales, continued DNA/protein growth and recurring gross-margin/OCF improvement
Dated reported financial evidence
Dated reported actuals; not current balances or forward forecasts. Units: reported USD millions unless a share count, ratio or date is explicitly named. These are not October 4 bank balances.
- balanceDate
- 2026-06-30
- cashUSDm
- 117.436
- shortTermSecuritiesUSDm
- 49.403
- liquidPoolUSDm
- 166.839
- restrictedCashExcludedUSDm
- 2.13
- nonLiquidEquityInvestmentExcludedUSDm
- 68.087
- fundedBorrowingOnBalanceSheetUSDm
- 0
- futureRevenueLiabilitySeparateUSDm
- 15
- leasesUSDm
- 93.59
- Q3RevenueUSDm
- 118.376
- Q3PriorRevenueUSDm
- 96.057
- YTD9RevenueUSDm
- 332.789
- Q3NetLossGAAPUSDm
- -35.051
- YTD9OCFUSDm
- -41.258
- YTD9CashCapexUSDm
- 27.624
- YTD9FCFDerivedUSDm
- -68.882
- YTD9SBCExpenseUSDm
- 50.385
- Q3SBCExpenseUSDm
- 18.176
- ordinaryShares
- 62,707,424
- ordinaryShareDate
- 2026-07-29
- Q3WeightedLossEPSshares
- 62,403,000
- YTD9WeightedLossEPSshares
- 61,726,000
- unvestedRSUshares
- 2,603,000
- optionShares
- 999,000
- optionsWeightedStrikeUSD
- 33.15
Target burdens — static sensitivities, not forward fair value
Static reverse burden not forward fairvalue/funded hitcase; unknown actual current claims/cash not replaced by these dated balances.
1.35× baseline · USD 253.868
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 62.707
- datedLiquidityUSDm
- 166.839
- datedDebtUSDm
- 0
- requiredCommonEquityUSDm
- 15,919.377
- staticEVUSDm
- 15,752.538
conditional priced offering closing
completion not verified; cash and shares credited together; stub unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 66.301
- datedLiquidityUSDm
- 493.939
- datedDebtUSDm
- 0
- requiredCommonEquityUSDm
- 16,831.714
- staticEVUSDm
- 16,337.775
conditional offering closing plus gross known options/RSUs
Unverified closing; paired cash/shares; zero exercise proceeds; not current FD, complete upper bound or funded target. ·
- datedSharesM
- 69.903
- datedLiquidityUSDm
- 493.939
- datedDebtUSDm
- 0
- requiredCommonEquityUSDm
- 17,746.144
- staticEVUSDm
- 17,252.205
2× baseline · USD 376.1
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 62.707
- datedLiquidityUSDm
- 166.839
- datedDebtUSDm
- 0
- requiredCommonEquityUSDm
- 23,584.263
- staticEVUSDm
- 23,417.424
conditional priced offering closing
completion not verified; cash and shares credited together; stub unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 66.301
- datedLiquidityUSDm
- 493.939
- datedDebtUSDm
- 0
- requiredCommonEquityUSDm
- 24,935.872
- staticEVUSDm
- 24,441.933
conditional offering closing plus gross known options/RSUs
Unverified closing; paired cash/shares; zero exercise proceeds; not current FD, complete upper bound or funded target. ·
- datedSharesM
- 69.903
- datedLiquidityUSDm
- 493.939
- datedDebtUSDm
- 0
- requiredCommonEquityUSDm
- 26,290.584
- staticEVUSDm
- 25,796.645
5× baseline · USD 940.25
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 62.707
- datedLiquidityUSDm
- 166.839
- datedDebtUSDm
- 0
- requiredCommonEquityUSDm
- 58,960.656
- staticEVUSDm
- 58,793.817
conditional priced offering closing
completion not verified; cash and shares credited together; stub unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 66.301
- datedLiquidityUSDm
- 493.939
- datedDebtUSDm
- 0
- requiredCommonEquityUSDm
- 62,339.68
- staticEVUSDm
- 61,845.741
conditional offering closing plus gross known options/RSUs
Unverified closing; paired cash/shares; zero exercise proceeds; not current FD, complete upper bound or funded target. ·
- datedSharesM
- 69.903
- datedLiquidityUSDm
- 493.939
- datedDebtUSDm
- 0
- requiredCommonEquityUSDm
- 65,726.46
- staticEVUSDm
- 65,232.521
Target-specific terminal shares: Unknown (null). Target-specific terminal cash: Unknown (null).
Discovery chart context
leadership · QQQ-relative discovery only, separate from AI100 runtime SPY scoring. Retained Oct1/Oct2 observations retrieved Oct4; no numerical rank against all incumbents.
- return20d
- 0.461
- return60d
- 1.008
- return120d
- 2.733
- distanceHigh
- -0.061
- range20d
- 0.667
- relative60d
- 0.981
Risks and unresolved inputs
- Actual October 4 opening cash/share drift from last balance/cover date; bounded signed elapsed-stub OCF, capex, working capital, award exercises and financing
- Price-dependent award/option/PSU and future issuance/replenishment bridge, vesting and exercise timing
- Compatible current expectations/valuation baseline and full retained boundary/top-five candidate economic cards; ordinal comparison is not verified by existing ticker orders
- August offering closing receipt/actual net proceeds and post-offer shares
- Detailed Q3/FY2026 issuer outlook and performance-award population/strikes
- Future-revenue contract cash obligations and Invenra tech-transfer settlement status
+35% Upside strongest countercase
CSCO already has ~$4bn recognized hyperscaler AI sales and a retained 26.5x operating bull below compatible current28.79x. TWST has no verified quantified AI backlog, is expensive, has no firm new event date, and its August offering closing remains conditional.
- TWST-news
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-submissions
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-Q3-alt
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-Q3-pdf
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-10Q
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-Aug19
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-Aug18
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-TuneLab
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied - TWST-Aug5
Published: Unknown — undated / publication time not supplied · Retrieved: Unknown — not supplied